capecitabine has been researched along with Shock, Septic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Becker, K; Bethe, U; Bleiberg, H; Bokemeyer, C; Braumann, D; De Greve, J; Debois, M; Hartmann, JT; Janssens, J; Joosens, E; Köhne, CH; Lang, I; Link, H; Müller, L; Reimer, P; Späth-Schwalbe, E; Van Cutsem, E; Van Den Brande, J; Vergauwe, P; Wilke, HJ | 1 |
1 trial(s) available for capecitabine and Shock, Septic
| Article | Year |
|---|---|
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Diarrhea; Double-Blind Method; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Prospective Studies; Pulmonary Embolism; Pyrazoles; Shock, Septic; Sulfonamides; Survival Analysis | 2008 |